NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company focused on developing nanomaterials for antiviral therapy, announced today that it will participate in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City. Anil R. Diwan, Ph.D., president and executive chairman, will host one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET.
The conference provides an opportunity for NanoViricides to showcase its lead drug candidate, NV-387, a broad-spectrum antiviral drug that the company plans to develop for the treatment of respiratory syncytial virus (RSV), COVID-19, Long COVID, Influenza, and other respiratory viral infections. NV-387 has demonstrated efficacy in animal models for Monkeypox (MPox), Smallpox, and Measles, highlighting its potential as a versatile therapeutic agent.
NanoViricides is also advancing NV-HHV-1, a drug candidate for the treatment of all Herpesvirus infections, including HSV-1 “cold sores”, HSV-2 “genital ulcers”, and VZV Shingles and Chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is currently focused on advancing NV-387 into Phase II human clinical trials, a critical step toward regulatory approval and eventual commercialization.
The D. Boral Capital Global Conference offers a platform for NanoViricides to engage with the investment community and discuss its pipeline and strategic direction. The event is expected to attract institutional investors, analysts, and industry experts, providing NanoViricides with visibility and potential funding opportunities.
For more information about NanoViricides and its latest news, visit the company’s newsroom at https://ibn.fm/NNVC.
This announcement comes as the company continues to navigate the clinical development process, with a focus on addressing unmet medical needs in antiviral therapy. The successful progression of NV-387 could have significant implications for patients suffering from respiratory viral infections and other viral diseases.
